At a glance
ClinicalIndex Comparison RecordN/ACompleted· 120 enrolled
Drug / intervention
Phasix™ STdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Multi-center Trial of a Long-term Bio-Absorbable Mesh With Sepra Technology in Challenging Laparoscopic Ventral or Incisional Hernia Repair
In Brief
A clinical study evaluating Phasix™ ST for Hernia, Ventral and Incisional Hernia. Completed, enrolled 120 participants across 16 sites.
Detailed Summary
The objective of this study is to collect additional data on safety, performance and effectiveness of Phasix™ ST in subjects receiving laparoscopic ventral or incisional hernia repair at high risk for surgical site occurrence (SSO).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHernia, Ventral, Incisional Hernia
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 2016
Enrollment StartApr 2016
Primary CompletionNov 2019
TodayJul 2026
First PostedMar 18, 2016
Enrollment StartApr 1, 2016
Primary CompletionNov 15, 2019
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 10.3 years ago
Interventions
Phasix™ STdevice
Phasix™ ST is a fully resorbable mesh with a hydrogel coating that is also resorbable.